Search research articles
Contact Us
Filters
Showing results (81-90 of 87) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 87 results.
JCO Precision Oncology
|
July 12, 2021
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer
Edmond M Kwan, Chao Dai, Heidi Fettke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard, Michael S Gordon, Sunil Sharma, et al.
Ebiomedicine
|
December 27, 2019
The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
Benoit You, Frédéric Mercier, Eric Assenat, et al.
Molecular Cancer Therapeutics
|
March 5, 2024
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
Adam M Kase, Justyna Gleba, James L Miller, et al.
BMC Medicine
|
March 25, 2022
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
Blossom Mak, Hui-Ming Lin, Edmond M Kwan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2017
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Manish Kohli, Yeung Ho, David W Hillman, et al.
Nature Communications
|
November 5, 2021
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer
Meixia Che, Aashi Chaturvedi, Sarah A Munro, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 87) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 87 results.
JCO Precision Oncology
|
July 12, 2021
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer
Edmond M Kwan, Chao Dai, Heidi Fettke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard, Michael S Gordon, Sunil Sharma, et al.
Ebiomedicine
|
December 27, 2019
The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
Benoit You, Frédéric Mercier, Eric Assenat, et al.
Molecular Cancer Therapeutics
|
March 5, 2024
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
Adam M Kase, Justyna Gleba, James L Miller, et al.
BMC Medicine
|
March 25, 2022
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
Blossom Mak, Hui-Ming Lin, Edmond M Kwan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2017
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Manish Kohli, Yeung Ho, David W Hillman, et al.
Nature Communications
|
November 5, 2021
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer
Meixia Che, Aashi Chaturvedi, Sarah A Munro, et al.
Page
of 9